The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.